AU2011332031B2 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
AU2011332031B2
AU2011332031B2 AU2011332031A AU2011332031A AU2011332031B2 AU 2011332031 B2 AU2011332031 B2 AU 2011332031B2 AU 2011332031 A AU2011332031 A AU 2011332031A AU 2011332031 A AU2011332031 A AU 2011332031A AU 2011332031 B2 AU2011332031 B2 AU 2011332031B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
patient
radezolid
effective amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011332031A
Other languages
English (en)
Other versions
AU2011332031A1 (en
Inventor
Danping Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Subsidiary Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Subsidiary Corp filed Critical Melinta Subsidiary Corp
Publication of AU2011332031A1 publication Critical patent/AU2011332031A1/en
Assigned to MELINTA THERAPEUTICS, INC. reassignment MELINTA THERAPEUTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: RIB-X PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2011332031B2 publication Critical patent/AU2011332031B2/en
Assigned to MELINTA SUBSIDIARY CORP. reassignment MELINTA SUBSIDIARY CORP. Request to Amend Deed and Register Assignors: MELINTA THERAPEUTICS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011332031A 2010-11-24 2011-11-21 Pharmaceutical compositions Ceased AU2011332031B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41680710P 2010-11-24 2010-11-24
US61/416,807 2010-11-24
PCT/US2011/061643 WO2012071324A2 (en) 2010-11-24 2011-11-21 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2011332031A1 AU2011332031A1 (en) 2013-06-06
AU2011332031B2 true AU2011332031B2 (en) 2017-01-12

Family

ID=46146374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011332031A Ceased AU2011332031B2 (en) 2010-11-24 2011-11-21 Pharmaceutical compositions

Country Status (21)

Country Link
US (2) US20140088164A1 (enExample)
EP (1) EP2642996B1 (enExample)
JP (2) JP6370550B2 (enExample)
KR (1) KR101944124B1 (enExample)
CN (1) CN103391778B (enExample)
AU (1) AU2011332031B2 (enExample)
BR (1) BR112013012833A8 (enExample)
CA (1) CA2818249C (enExample)
EA (1) EA027791B1 (enExample)
ES (1) ES2836809T3 (enExample)
HU (1) HUE052801T2 (enExample)
IL (1) IL226378A0 (enExample)
MX (1) MX350565B (enExample)
MY (2) MY171941A (enExample)
NZ (1) NZ610638A (enExample)
PH (1) PH12013501069A1 (enExample)
PT (1) PT2642996T (enExample)
SG (2) SG10201509530YA (enExample)
UA (1) UA113722C2 (enExample)
WO (1) WO2012071324A2 (enExample)
ZA (1) ZA201303732B (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046992A1 (en) * 2000-03-22 2001-11-29 Batts Donald Herman Treatment of urinary tract infections with antibacterial oxazolidinones
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US20080213366A1 (en) * 2005-04-29 2008-09-04 Cubist Pharmaceuticals, Inc Therapeutic Compositions
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
WO2012061360A2 (en) * 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
EP1265608B1 (en) * 2000-03-22 2008-10-29 Pharmacia & Upjohn Company LLC Oxazolidinone tablet formulation
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
EP1912730A2 (en) 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
CN101378731B (zh) * 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂
US20120208857A1 (en) * 2009-10-13 2012-08-16 Burak Eric S Pharmaceutical Compositions
WO2011159626A1 (en) * 2010-06-14 2011-12-22 Bend Research, Inc. Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046992A1 (en) * 2000-03-22 2001-11-29 Batts Donald Herman Treatment of urinary tract infections with antibacterial oxazolidinones
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US20080213366A1 (en) * 2005-04-29 2008-09-04 Cubist Pharmaceuticals, Inc Therapeutic Compositions
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
WO2012061360A2 (en) * 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2836809T3 (es) 2021-06-28
JP6370550B2 (ja) 2018-08-08
HUE052801T2 (hu) 2021-05-28
MX350565B (es) 2017-09-11
US20160374995A1 (en) 2016-12-29
BR112013012833A8 (pt) 2018-01-02
CN103391778B (zh) 2016-04-20
EP2642996A4 (en) 2014-05-21
MY171941A (en) 2019-11-08
ZA201303732B (en) 2018-12-19
MY182136A (en) 2021-01-18
NZ610638A (en) 2015-05-29
PT2642996T (pt) 2020-12-30
AU2011332031A1 (en) 2013-06-06
WO2012071324A3 (en) 2012-08-16
KR20140033314A (ko) 2014-03-18
EP2642996B1 (en) 2020-09-23
WO2012071324A2 (en) 2012-05-31
MX2013005813A (es) 2013-09-13
BR112013012833A2 (pt) 2016-08-23
CA2818249A1 (en) 2012-05-31
CA2818249C (en) 2021-04-13
SG190354A1 (en) 2013-06-28
JP2013543893A (ja) 2013-12-09
EA201390764A1 (ru) 2013-09-30
US20140088164A1 (en) 2014-03-27
PH12013501069A1 (en) 2013-07-08
SG10201509530YA (en) 2015-12-30
UA113722C2 (uk) 2017-03-10
CN103391778A (zh) 2013-11-13
IL226378A0 (en) 2013-07-31
EA027791B1 (ru) 2017-09-29
KR101944124B1 (ko) 2019-01-30
JP2017081950A (ja) 2017-05-18
US10300046B2 (en) 2019-05-28
EP2642996A2 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
AU2016234893A1 (en) Pharmaceutical Compositions
WO2012061360A2 (en) Pharmaceutical compositions
AU2021286284B2 (en) Antimicrobial compositions with effervescent agents
US10300046B2 (en) Pharmaceutical compositions
HK1230972A1 (en) Pharmaceutical compositions comprising radezolid
HK1230972A (en) Pharmaceutical compositions comprising radezolid
HK40065457A (en) Antimicrobial compositions with effervescent agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: MELINTA SUBSIDIARY CORP.

Free format text: FORMER NAME(S): MELINTA THERAPEUTICS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired